Antitissue transglutaminase antibodies in acute coronary syndrome: an alert signal of myocardial tissue lesion?
- 7 December 2007
- journal article
- clinical trial
- Published by Wiley in Journal of Internal Medicine
- Vol. 263 (1), 43-51
- https://doi.org/10.1111/j.1365-2796.2007.01881.x
Abstract
Background and aim. Antitransglutaminase, previously considered identical to antiendomysial in coeliac sprue (CS), have been reported in end-stage heart failure. To clarify the above-mentioned data, we evaluated these antibodies in a cohort of cardiological patients with respect to troponin I, creatine kinase (CK), MB fraction creatine kinase (CK-MB mass) and myoglobin. Methods. Forty-one patients with acute coronary syndrome (ACS), 39 with dilated cardiomyopathy (DCM), 45 with CS and 58 blood donors (BDs) were evaluated. Antitransglutaminase and antiendomysial antibodies were tested in serum of the patients being studied. Results. High-positive antitransglutaminase values were found in CS, whilst low-positive values were also found in ACS and DCM. In patients at the second ACS, antibody levels were higher than in those at the first cardiac event. In patients with infarct Q, antitransglutaminase were higher than those in infarct non-Q, in which antibody levels were higher than those in unstable angina. A correlation between antitransglutaminase and troponin I, CK, CK-MB mass and myoglobin was found. Finally, antibody levels rose to reach a peak at 30 days from the cardiac event, whereas after further 150 days, approached the values of BDs. Antiendomysial were detectable only in CS. Conclusions. Data highlight that antitransglutaminase can occur in cardiological patients, and that these antibodies are related to the severity/extent of the myocardial tissue lesion. This feature suggests a loss of specificity for antitransglutaminase in CS. Furthermore, the possibility of employing these antibodies in the long-term follow-up of ACS, could become an object of interesting discussionKeywords
This publication has 19 references indexed in Scilit:
- Roles of transglutaminases in cardiac and vascular diseasesFrontiers in Bioscience-Landmark, 2007
- Celiac Disease Prevalence in Brazilian Dilated Cardiomyopathy PatientsDigestive Diseases and Sciences, 2006
- The role of tissue transglutaminase in cell-matrix interactionsFrontiers in Bioscience-Landmark, 2006
- Type 2 Transglutaminase and Cell DeathPublished by S. Karger AG ,2005
- Identification of new celiac disease autoantigens using proteomic analysisProteomics, 2003
- Presence of anti-‘tissue’ transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event?Cell Death & Differentiation, 2001
- Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial InfarctionEuropean Heart Journal, 2000
- Anti-tissue transglutaminase, anti-endomysium and anti-R1-reticulin autoantibodies—the antibody trinity of coeliac diseaseClinical and Experimental Immunology, 1999
- Isolation of antigens recognized by coeliac disease autoantibodies and their use in enzyme immunoassay of endomysium and reticulin antibody-positive human seraClinical and Experimental Immunology, 1996
- Purification of Fibroblast-Derived Celiac Disease Autoantigen MoleculesPediatric Research, 1993